Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. Methods: This was a phase II, randomized, placebo-controlled parallel group study conducted at 37 US centers, consisting of an 8-week double-blind period followed by a 16-week open-label period. Patients were 137 women aged 18 to 49, with laparoscopically confirmed endometriosis and moderate to severe nonmenstrual pelvic pain and dysmenorrhea, who were administered elagolix 150 mg daily or placebo. The primary outcomes of the study were the daily assessment of dysmenorrhea, nonmenstrual pelvic pain and dyspareunia using a modified Biberoglu-Behrman scale. Results: During the double-blind period, there were significantly greater mean reductions from baseline to week 8 in dysmenorrhea (-1.13 ± 0.11 vs. −0.37 ± 0.11, p<0.0001), nonmenstrual pelvic pain (-0.47 ± 0.07 vs. −0.19 ± 0.07, p = 0.0066), and dyspareunia scores (-0.61 ± 0.10 vs. −0.23 ± 0.10, p = 0.0070) in the elagolix group compared with placebo. Continued improvements were observed during the open-label treatment regardless of initial treatment allocation. Elagolix treatment was also associated with significant improvements in quality-of-life measures during the double-blind and open-label periods. The most common adverse events occurring with elagolix were nausea, headache and hot flush, each in 9.9% of patients. Conclusion: Elagolix effectively reduced endometriosis-associated pelvic pain over a 24-week period and was well-tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo interventions for all clinical conditions
Hróbjartsson, A., & Gøtzsche, P. C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003974.pub3 · Cited by 777
Dlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Fourquet, J., Báez, L., Figueroa, M., Iriarte, R. I., & Flores, I. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.04.095 · Cited by 262 · cited 2×
“In addition, the pain related to endometriosis has been shown to impair both workrelated and non-work-related daily activities (4-6).”
BackgroundHealth-related quality of life burden of women with endometriosis: a literature review
Gao, X., Yeh, Y.-C., Outley, J., Simon, J., Botteman, M., & Spalding, J. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x121084 · Cited by 206
Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei290 · Cited by 179
Schlaff, W. D., Carson, S. A., Luciano, A., Ross, D., & Bergqvist, A. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.07.1315 · Cited by 168
Progestogens for endometriosis: forward to the past
Vercellini, P. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg030 · Cited by 147 · cited 2×
“Also contrary to injectable GnRH agonists or depot medroxyprogesterone acetate, which may be associated with a delay in the return of regular menses (24-26), resumption of menses was rapid after discontinuation of elagolix, which may be desirable in women who wish to conceive.”
BackgroundResultGonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
Cited by
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
Self-citationReevaluating response and failure of medical treatment of endometriosis: a systematic review
Becker, C. M., Gattrell, W. T., Gude, K., & Singh, S. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.004 · Cited by 302
“5 RCT (n 1⁄4 3) (51, 52, 53) Industry (n 1⁄4 3) Medical and surgical treatment 13 1992–2014 3,198 3–24 RCT (n 1⁄4 7) (54, 55, 56, 57, 58, 59, 60); prospective cohort study (n 1⁄4 2) (61, 62); prospective case-control study (n 1⁄4 2) (63, 64); retrospective study (n 1⁄4 2) (65, 66) Nonindustry (n 1⁄4 11); partial indus…”
Ng, J., Chwalisz, K., Carter, D. C., & Klein, C. E. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3845 · Cited by 110
Self-citationElagolix: First global approval
Lamb, Y. N. (2018) · Drugs · doi:10.1007/s40265-018-0977-4 · Cited by 104
“Key clinical trials of elagolix, sponsored by AbbVie Drug(s) Indication Phase Status Location(s) Identifier Elagolix ± estradiol/NETA Moderate to severe endometriosis-associated pain III Recruiting USA; Canada NCT03343067; M16-383 Elagolix ± estradiol/ NETA, placebo Moderate to severe endometriosis-associated pain III…”
BackgroundMethodInfluentialA comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
Metadata
- Authors
- Carr, B., Giudice, L., Dmowski, W. P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., Hass, S., Fuldeore, M., & Chwalisz, K.
- Venue
- Journal of Endometriosis and Pelvic Pain Disorders
- Publisher
- SAGE Publications
- Published
- 2013-07
- Volume
- 5
- Issue
- 3
- Pages
- 105-115
- ISSN
- 2035-9969 (ISSN-L)
- 2284-0265
- 2284-0273
- OpenAlex
- W2062637361
- Cited by
- 64
- References
- 9
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.